I marts 2006 indgav Intervet herefter en ansøgning om markedsføringstilladelse for vaccinen ved gentagelse af den gensidige anerkendelsesprocedure med Tyskland som referencemedlemsstat for Danmark, Polen, Slovakiet og Slovenien.
In March 2006 Intervet then submitted an application for a marketing authorisation for this vaccine following a repeat use mutual recognition procedure, with Germany acting as Reference Member State, for Denmark, Poland, Slovakia and Slovenia.